An open label, multi-centre study of pasireotide LAR in addition to chemotherapy in patients with non-functioning, endocrine pancreatic tumors.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2012
At a glance
- Drugs Pasireotide (Primary) ; Antineoplastics
- Indications Endocrine gland neoplasms; Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 29 Jul 2011 New trial record